Objective: The purpose of this study was to determine the incidence of new-onset pelvic pain within 2 years after either radiofrequency (RF) or thermal balloon (TB) endometrial ablation for menorrhagia. Study design: This study was a retrospective cohort study of consecutive patients treated by radiofrequency or thermal balloon global endometrial ablation (GEA) between 2003 and 2008. Setting: The study took place in an inner-city, academic teaching hospital (RF cohort), inner-city community-based obstetrics and gynecology private practice (TB cohort). Intervention: Procedures performed were hysteroscopy and endometrial ablation by either radiofrequency (under general anesthesia) or thermal balloon (under local paracervical block). Outcome measure: The primary outcome measure was the incidence of new-onset pelvic pain at 3, 6, 12, 18, and 24 months, and the secondary outcome measure was the mean visual analogue scale (VAS) pain score per modality, per time endpoint. Results: De novo pelvic pain occurred overall in 20% of RF and 7% TB ( p-value = 0.01). The incidence of pain was greater after RF than after TB at each time endpoint ( p-value = 0 < .05). The radiofrequency cohort had a statistically significant increase in pain incidence at 3-6 ( p-value = 0.02), and 6-12 months ( p-value = 0.03), with similar findings occurring with thermal balloon between 6 and 12 months ( p-value = 0.03). Mean VAS was greater after radiofrequency, at each time endpoint. Conclusions: De novo pelvic pain frequency and severity differ by mode of therapy after GEA. The possibility of de novo pelvic pain after treatment should be reviewed with the patient preprocedure. ( J GYNECOL SURG 27:203) 
Introduction
P reviously, the current authors have had articles published reporting menstrual outcomes as well as dysmenorrhea reduction after in-office thermal balloon (TB) ablation. 1, 2 Although reduction in dysmenorrhea reduction and pelvic pain have been well-documented following global endometrial ablation (GEA), [1] [2] [3] [4] no previously published literature regarding the incidence or severity of de novo pelvic pain after GEA therapy for menorrhagia has been found. The current study was conducted to determine the incidence, severity, and differences (if any) in de novo pelvic pain after GEA by two common modalities: radiofrequency (RF; Novasure, Hologic Bedford, MA) and TB (Thermachoice III,Ò Gynecare, Somerville, NJ).
Materials and Methods
This was a retrospective cohort analysis of all Women's Specialty Center (WSC) Dallas (TX) patients treated for menorrhagia between 2003 and 2008. The study was approved by the internal ethics review board of WSC Dallas.
Patient charts was pulled from WSC's central database after meeting a search criteria of ''abnormal uterine bleeding, dysfunctional uterine bleeding, menorrhagia, or menometrohagia'' linked to endometrial ablation, as noted by Current Procedural Terminology codes, during that time period. WSC standard protocol for GEA included RF as the treatment choice from 2003 to 2005, and a switch was made to TB in 2006 as the treatment offered in office. Patients in the RF cohort were treated under general anesthesia in a day-surgery facility, whereas those treated with TB were given a local paracervical block in an office setting. The preoperative evaluation did not differ between cohorts, as the same preoperative protocol has been used at WSC since GEA adoption in the timeframe stated. The current authors have previously had an article published on this preoperative evaluation, inclusion, and exclusion criteria for GEA patients. 5 In brief, patients included were those who did not desire hysterectomy as their initial mode of treatment. Exclusion criteria were postmenopausal status, premalignant or malignant endometrial histology, prior classic cesarean section or other corporal transmural uterine surgery, Women's Specialty Center and Department of Obstetrics/Gynecology, Methodists' Medical Center, Dallas, TX.
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uterine size outside the written protocol ( > 12 cm sagittal cervix to fundal sonographic measurement), desire for future fertility, or intramural/submucosal fibroid size > 4 cm. Patients underwent endometrial ablation with either technology without either menstrual cycle timing, or endometrial medical preparation. However, all patients (each cohort) underwent concomitant dilatation and curettage with a Novak (Berkeley Medevices, Inc. Richmond, CA) curette at time of the ablation. For this reason, no patients underwent medical pretreatment for endometrial-lining thickness as a treatment protocol.
Per the standard protocol, postoperative GEA patients were seen in an office at 2 weeks and at 3, 6, 12, 18, and 24 months for evaluation of menstrual outcomes (as noted in patient diaries) and pelvic pain reduction or new-onset occurrence (as noted on a visual analogue scale [VAS] recording). Patients who were not evaluated by in-office appointment were contacted by WSC medical staff members by phone to complete data collection. For this study, 3-24 month clinical outcomes were reported. For each evaluable cohort, menstrual outcomes postablation with data gathered by patient menstrual diaries/reporting, rather than by Pictorial Blood Loss Assessment charts, were analyzed. Figure 1 details the patient inclusion/exclusion triage for this study.
Statistical analysis
The sociodemographic profile of each original treatment group was compared using descriptive statistics (X2 and Fisher's exact test for all categorical data and Student's t-test for continuous data). Student's t-tests were used to compare mean differences in pelvic-pain incidence at each timepoint between the two groups (primary endpoint), as well as differences in mean VAS scores at each timepoint per group (secondary endpoint). Paired t-tests were used to analyze intragroup differences at each timepoint for both incidence and VAS scores. Statistics were completed via Graphpad Data Analysis and Biostatistics Softwares (La Jolla, CA).
Effects of potential confounding factors on pelvic pain such as age, sexually transmitted disease (STD) diagnosis, new-onset adnexal masses, or possible depression were also taken into account.
Results
There were no statistically significant sociodemographic differences between the two cohorts pretreatment or in the final evaluable cohorts (post-therapy; Table 1 ). Initially, 221 and 204 patients were treated by RF and TB, respectively. In the RF cohort, 92% (n = 42) were evaluated in the office, and 8% (n = 4) were evaluated by telephone to complete the
FIG. 1.
Patients treated by global endometrial ablation (GEA) postoperative triage. RF, radiofrequency; TB, thermal balloon; Hx, history; PID, pelvic inflammatory disease; STDs, sexually transmitted diseases; Pts, patients; UTIs, urinary-tract infections; GC, gonorrhea, chlamydia; sxs, symptoms.
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postoperative follow-up protocol. For the TB cohort, 86% (n = 12) were evaluated postoperatively in the office, and 14% (n = 2) were contacted by telephone to complete the postoperative protocol. Overall, during the study period, 30 RF patients (34%) and 47 TB patients (72%) did not report de novo pelvic pain up to 24 months post-therapy. Those reporting new-onset pelvic pain were then screened for any confounding variables and excluded from the final evaluable cohort ( Fig. 1) , leaving an incidence of de novo pain in 46/221 RF (20%) and 14/204 TB patients (7%; p value = 0.1). As Figure 2 shows, the incidence of pain was greater after RF than after TB at each time endpoint ( p values = 0.02 at 3, 0.01 at 6, 0.03 at 12, 0.02 at 18, and 0.01 at 24 months). The RF cohort had a statistically significant rise in pain incidence at 3-6 ( p-value = 0.02) and at 6-12 months ( p-value = 0.03), with similar findings occurring with TB between 6 and 12 months ( p-value = 0.03). Figure 3 depicts mean VAS scores per cohort, per each time endpoint. Extrapolation from Figure 3 reveals a downward trend in mean VAS in the RF cohort toward the study's end, and a plateau in VAS scores in the TB cohort. No other intracohort significant differences were noted at other timepoints. In a subanalysis, patients with uterine fibroids were evaluated with respect to both incidence and severity (VAS scores) of de novo pelvic pain, at each endpoint. As shown in Table 1 , no statistically significant difference was noted between the cohorts experiencing de novo pain despite fibroid presence ( p = 0.8). Table 2 depicts both the VAS scores and incidence per timepoint for each treatment cohort in this fibroid subanalysis. Because of limited numbers in either group (RF n = 15 and TB n = 4), limited conclusions/calculations were derived from this subgroup analysis.
Menstrual outcomes during the study period were as follows: in the RF evaluable group (n = 46), amenorrhea was reported in 48% (n = 22/46), hypomenorrhea/eumenorrhea was reported in 56% (n = 23/46), and 1 patient reported no change in menstruation (2%). For the TB group (n = 14): amenorrhea was reported in 57% (8/14) with the reminder reporting hypomenorrhea/eumenorrhea (43%, 6/14).
Mean VAS was greater after RF than after TB, at each time endpoint. However, a statistically significant difference in VAS was noted between the two groups only at 3, 6, and 12 months (Table 3 ). Paired t-tests for intragroup differences in VAS at each timepoint revealed a statistically significant increase in VAS at 3-6 months for both groups ( p = 0.02 FR, p = 0.01 TB). Peak VAS scores (highest discomfort) were reported for both groups at 6 months, with a mean VAS of 6 for RF and 3 for TB. Fifteen of 23 (63%) RF and 6/14 
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(42%) TB patients stated that the symptoms interfered with either work/school activities or interpersonal/social interactions.
Discussion
GEA was first introduced in 1994 as an alternative to rollerball endometrial destruction. 6 Since GEA's introduction, many have reported on baseline dysmenorrhea with regard to its post-therapy reduction, 7, 8 and as a marker for possible success/failure postablation. 9 Sporadic reports in the literature have described de novo dysmenorrhea after rollerball endometrial destruction. 10 However, other published work describing this scenario-de novo pelvic pain after GEA among treated patients-was not found. The current study was conducted to explore the possibility of this occurrence and its incidence and severity after two common GEA therapies: RF and TB.
Interestingly, a statistically significant occurrence of de novo pelvic pain after RF (20%), compared to TB (7%) overall, with an increased incidence at all timepoints up to 24 months, was found. In addition, mean VAS results were statistically higher after RF from 3 to 12 months posttherapy. Although both treatment groups had their respective maximum mean VAS scores at 6 months, the RF group maximum mean was 6, compared to 3, for the TB group (a statistically significant difference). This must be interpreted with the preaccepted cutoffs along the VAS continuum, where 0-3 is interpreted as ''mild,'' 4-6 as ''moderate,'' and 7-10 as ''severe.'' 11, 12 The increased incidence and the VAS difference between cohorts cannot be explained by the design of this study. These occurrences are unlikely to be a result of the depth of the myometrial treatment zone, as users of both modalities reported a maximum depth of fundal myometrial penetration between 4 and 6 mm. 13, 14 In addition, it is unlikely to result from changes in amenorrhea rates, as both U.S. Food and Drug Administration (FDA) pivotal trials have reported comparable rates of 36% (RF) and 37% (TB) intention-totreat. 13, 14 In the cohorts reported here, a clear association between pain development and menstrual outcomes also could not be reached, as both cohorts had clinically similar outcomes and menstrual histories with no overt differences. Whether the incidence in de novo pain is related to uterine cavity or cervical effects (stenosis), altered sensitivity to prostaglandins, newly developed adenomyosis, or potential hematometria can only be a matter of speculation at this point. It must be noted, however, that, based on the triage algorithm used, the remaining cohorts for final evaluation had a negative pain workup, including cervical cultures and pelvic vaginal ultrasounds.
As its major strength, this article is the first of its kind to identify a potential syndrome/clinical symptom complex after GEA with RF and TB. The possibly of this occurring after other modes of GEA (cryoablation, microwave ablation, or circulating heated fluid/hydrotherm-ablation [HTA]) was not mentioned, as they were not used in the study authors' practice during the study terms. In addition, treatment/selection bias was reduced, as standard patient inclusion/exclusion criteria, preoperative evaluation, and routine followup did not vary during the study period. Furthermore, by a standing triage algorithm (Fig. 1) , patients with potential confounding etiologies for pelvic-pain syndromes were be eliminated. Of note, the utilization of ''pelvic pain'' as the chief endpoint over ''dysmenorrhea'' allows for a more global and practical means of capturing patients, as those with either amenorrheic or hypomenorrehic resulting patterns may be unable to relate their symptoms as ''painful periods,'' because of their absence. Finally, it was demonstrated that such pain syndromes caused interference with daily life activities in 15/24 (63%) RF and 6/14 (42%) TB patients, although a validated heath related Quality of Life Scale was not used. This study's limitation is its retrospective rather than prospective design. However, the algorithm described previously aids in bias reduction. In addition, to reduce bias further, the data were collected and compiled by a member not participating directly in the analysis or authorship of this article. What is more, the study design prevents the possibility of proposing any hypothesis about the etiology of the pelvic-pain symptoms. Also, this study was not designed to RF n = 15 (33% of subject cohort). TB n = 4 (28% of subject cohort). *Values are mean (standard deviation): 0 = no pain, 100 = worst pain imaginable. VAS score is based on 100-mm line scale.
RF, radiofrequency; TB, thermal balloon, VAS, visual analogue score. 
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assess or describe any subsequent treatment necessary (hysterectomy, medical therapy, or other uterine intervention) because of pelvic pain. Again, this was not the focus of this current study. A future article is planned by the same authors detailing those points, on follow-up therapies from these cohorts, including pathologic examinations of extirpated uteri when available. Although not suggested here, it is important to acknowledge a potential hypothesis about origin of these de novo pain syndromes. Based on accepted expert opinion, such de novo pain syndromes may be caused by many factors, such as cervical stenosis, uterine cavity or cervical adhesions, and/or ischemic changes in the adjacent myometrium caused by vascular coagulation in the absence of other anatomic changes or the combination of them. In addition, possible causation of pain in the RF cohort was the pretreatment dilatation and curettage, which were performed concomitantly. It is conceivable that the procedure, by permitting better penetration of radiofrequency (RF) energy in the myometrial layer, resulted in greater thermal injury and therefore deeper ischemia in this layer, favoring increased chances of subsequent pain. However, this must be recognized as a hypothesis only, until extirpative pathologic examination reveals the true etiology, if any, of this pain. It must also be recognized that patients whose uteri were up to 12-cm size as seen on sonographic measurement were not excluded. ''Larger uteri'' were included in the treatment algorithm because of the multiparous (or grand multiparous) patient characteristics of the clinic population, who have these real-world uterine dimensions. However, it must be stated that, based on this current study design, patients with subclinical adenomyosis presenting with enlarged uteri may have been incorporated into the groups. Again, this will be the focus of the authors' next manuscript on the postablation, subsequent therapies for these pain patients. It is the hope of the authors that this article, the first in the literature to report on such an occurrence, will stimulate interest in further prospective trials with larger patient numbers to define clinical cases such as these better.
Conclusions
In closing, as more focus is being placed on improved quality of life measures rather than just menstrual patterns postablation, 15, 16 de novo pelvic pain occurrence and severity after two common GEA technologies have been documented. The incidence as well as its associated severity varies by mode of therapy (RF > TB). The possibility of de novo pelvic pain after treatment should be reviewed with patients preprocedure.
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